Elite Pharmaceuticals Inc: Form 10-Q for the period ended Jun 30, 2024
Filed with the SEC on Aug 14, 2024 and accepted by EDGAR at Aug 14, 2024, 20:05 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-04-01 to 2024-06-30 | $18.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2024-04-01 to 2024-06-30 | $10.3m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2024-04-01 to 2024-06-30 | $8.5m | us-gaap:GrossProfit |
| Research and development | 3 months2024-04-01 to 2024-06-30 | $2.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-04-01 to 2024-06-30 | $3.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-04-01 to 2024-06-30 | $232.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-04-01 to 2024-06-30 | $615.8k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-04-01 to 2024-06-30 | $0.00 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-04-01 to 2024-06-30 | $0.00 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-04-01 to 2024-06-30 | 1,076,250,204 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2024-04-01 to 2024-06-30 | $3.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2024-04-01 to 2024-06-30 | $778.5k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-06-30 | $8.4m | us-gaap:Cash |
| Current assets | At period end2024-06-30 | $43.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-06-30 | $87.8m | us-gaap:Assets |
| Current liabilities | At period end2024-06-30 | $14.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-06-30 | $29.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-06-30 | $58.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-24-032154. Last ingested by Listed: Oct 24, 2026, 15:03 ET. Listed shows no prices and gives no investment advice.